Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices sanofi Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices sonofi O Q1 2022 Results Play to Win April 28, 2022 Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices Forward-looking statements This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forwardlooking ...

Sanofi SA (NASDAQ:SNY) Q1 2022 Earnings Conference Call April 28, 2022 8:30 AM ET Company Participants Eva Schaefer-Jansen - Head, IR Paul Hudson - CEO & Director John Reed - EVP & Global Head, Research & Development William Sibold - EVP, Specialty Care & President, Sanofi North America Thomas Triomphe - Head, Vaccines Olivier Charmeil - Head, General Medicines Julie Van Ongevalle - EVP, Consumer Healthcare Jean-Baptiste de Chatillon - EVP & CFO Brendan OÂ'Callaghan - EVP, Global Industrial Affairs Conferen ...

Exhibit 99.1 Information Statement DISTRIBUTION OF SHARES OF EUROAPI TO THE SHAREHOLDERS OF SANOFI This information statement is intended to provide shareholders of Sanofi ("Sanofi") in specified jurisdictions other than France (as set forth under "Notice to Prospective Shareholders of EUROAPI", the "Jurisdictions") with information relating to the proposed pro rata distribution of approximately 58% of the outstanding shares of the EUROAPI company ("EUROAPI" or the "Company") by Sanofi to its shareholders ( ...

sanofi ● Immunology Investor Event Cambridge, MA ● March 29, 2022 Forward-looking statements This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forwardlooking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, se ...

sanofi sanofi ● Tolebrutinib Investor Call ACTRIMS Forum 2022 February 24-26 | West Palm Beach, Florida ● February 25, 2022 Forward-looking statements This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forwardlooking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with r ...

Sanofi (NASDAQ:SNY) Cowen 42nd Annual Healthcare Conference Call March 9, 2022 11:10 AM ET Company Participants Dietmar Berger - Chief Medical Officer Conference Call Participants Stephen Scala - Cowen & Company Michael Nedelcovych - Cowen & Company Stephen Scala Well, good morning and welcome to the Sanofi session of Cowen's 42nd Annual Healthcare Conference. We're very pleased to have Sanofi back again with us this year. Representing the company, Dietmar Berger, who is Chief Medical Officer. For those cli ...

. FORM 20-F 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR ...

Transforming to deliver Business update Financial performance Outlook Appendices sanofi Transforming to deliver Business update Financial performance Outlook Appendices sonofi O Q4 and Full Year 2021 Results Play to Win February 4th, 2022 Transforming to deliver Business update Financial performance Outlook Appendices Forward-looking statements This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forwardlooking statements are state ...

Sanofi (NASDAQ:SNY) Q4 2021 Results Conference Call February 4, 2022 7:30 AM ET Company Participants Eva Schaefer-Jansen - Head, IR Paul Hudson - CEO Bill Sibold - Global Business Unit Head Thomas Triomphe - Global Business Unit Head Olivier Charmeil - Global Business Unit Head Julie Van Ongevalle - Global Business Unit Head Jean-Baptiste de Chatillon - CFO John Reed - EVP, Global Head of Research & Development Conference Call Participants Wimal Kapadia - Bernstein Richard Vosser - JP Morgan Luisa Hector - ...

Exhibit 99.1 Sanofi announces positive Phase 1/2 study interim results for its first mRNA- based vaccine candidate PARIS – September 28, 2021 – Positive interim results from a Phase 1/2 study1 of Sanofi's mRNA-based COVID-19 vaccine candidate confirm the potential of recently-acquired Translate Bio's messenger RNA (mRNA) and lipid nanoparticle (LNP) platform and support Sanofi's mRNA strategy. The initial data from Phase 1/2 showed neutralizing antibody seroconversion (defined as 4-fold increase vs baseline ...